Dialysis and transplantation in fabry disease: Indications for enzyme replacement therapy

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 2, 2010, Pages 379-385

  Mignani, Renzo ^a   Feriozzi, Sandro ^b   Schaefer, Roland M ^c   Breunig, Frank ^d   Oliveira, João Paulo ^e   Ruggenenti, Piero ^f,g   Sunder Plassmann, Gere ^h  

^a Infermi Hospital   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF PORTO   (Portugal)

^f MARIO NEGRI INST PHARMACOL RES   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; GLOBOTRIAOSYLCERAMIDE;

CARDIOMYOPATHY; CASE FINDING; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PROTEINURIA; RENAL REPLACEMENT THERAPY; RISK FACTOR; SCREENING;

ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FABRY DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77749325037     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05570809     Document Type: Conference Paper

References (51)

1. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M: Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34: 236-242, 2004
2. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA III, Kopp JB: Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138, 2002
3. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP: Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry registry. Mol Genet Metab 93: 112-128, 2008
4. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M: Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24: 715-724, 2001
5. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750-760, 2001
6. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775, 2001
7. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P: Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry registry. Genet Med 11: 790-796, 2009
8. Mehta A, Clarke JTR, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G: Natural course of Fabry disease: Changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet 46: 548-552, 2009
9. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285: 2743-2749, 2001
10. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001
11. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT: Patients with Fabry disease on dialysis in the United States. Kidney Int 61: 249-255, 2002
12. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S: Kidney transplant outcomes in patients with Fabry disease. Transplantation 87: 280-285, 2009
13. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ: Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111, 2009
14. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO: Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354, 2006
15. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, longterm renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007
16. West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R: Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20: 1132-1139, 2009
17. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M: Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease. Am J Nephrol 29: 353-361, 2009
18. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C: Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23: 1600-1607, 2008
19. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG: End-stage renal disease in patients with Fabry disease: Natural history data from the Fabry registry. Nephrol Dial Transplant 2009 [Epub ahead of print]
20. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M: Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583, 2007
21. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 77-86, 2007
22. Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F: Report on management of renale failure in Europe, XXVI,: Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11[Suppl 7]: S4-20, 1996
23. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G: Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15: 1323-1329, 2004
24. Merta M, Reiterova J, Ledvinova J, Poupetova H, Dobrovolny R, Rysava R, Maixnerova D, Bultas J, Motan J, Slivkova J, Sobotova D, Smrzova J, Tesar V: A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 22: 179-186, 2007
25. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ: Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64: 801-807, 2003
26. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B: Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69: 2337-2339, 2000
27. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N: Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 22: 1920-1925, 2007
28. Kosch M, Koch HG, Oliveira JP, Soares C, Bianco F, Breuning F, Rasmussen AK, Schaefer RM: Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 66: 1279-1282, 2004
29. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, Pasquali S, Savoldi S, Comotti C, Cianciaruso B: Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement. Am J Kidney Dis 46: 120-127, 2005
30. Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L: Agalsidase therapy in patients with Fabry disease on renal replacement therapy: A nationwide study in Italy. Nephrol Dial Transplant 23: 1628-1635, 2008
31. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, Powe NR, Parekh RS: Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 54: 468-477, 2009
32. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 108: 1299 -1301, 2003
33. Widemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J: Longterm effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119: 524-529, 2009
34. Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, Cagnoli L: Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study. Kidney Int 65: 1381-1385, 2004
35. Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G: Kidney transplantation in patients with Fabry disease. Transpl Int 22: 475-481, 2009
36. Öqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG: Nephropathy in Fabry disease: The importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant 24: 1736-1743, 2009
37. Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H, Nakamura T, Kawabe M, Lino Y, Katayama Y: Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 4: 49-51, 2000
38. Desnick RJ: Fabry disease: unrecognized ESRD patients and effectiveness of enzyme replacement on renal pathology and function. Am J Hum Genet Suppl 71: 417, 2002
39. Spada M, Pagliardini S: Screening for Fabry disease in endstage nephropathies. J Inher Metabol Dis 25 [Suppl I]: 113, 2002
40. Pagliardini S, Canavese C, Locatelli F, Spada M: Prevalence of Fabry disease in male patients with end-stage nephropathy [Abstract]. Abstract presented at The European Symposium on Fabry Disease; November 8 to 9, 2002; Athens, Greece
41. Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW: alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 18: 1581-1584, 2003
42. Rocha S, Pinto R, Dickson J, Joao Pais M, Clara Sa Miranda M: Screening of Fabry in individuals submitted to haemodialysis [Abstract]. Abstract presented at Fabry 5th Round Table Meeting; October 22 to 23, 2004; Warsaw, Poland
43. Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y: Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9: 228-232, 2005
44. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P: Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 101: c33-c38, 2005
45. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K: Identification of Fabry's disease by the screening of alphagalactosidase A activity in male and female hemodialysis patients. Clin Nephrol 64: 281-287, 2005
46. Maslauskiene R, Bumblyte IA, Sileikiene E, Grazulis S, Laurinavicius A, Pleckaitis M, Alekniene D, Dobrovolskiene R, Vainauskas V, Juodeikiene L, Steckis R, Sakalauskiene M, Macius K, Urbanaviciene J, Labutiene V, Gaupsiene E, Ziaukiene G, Burbaickaja S, Gailiūnas J: The prevalence of Fabry's disease among male patients on hemodialysis in Lithuania (a screening study). Medicina (Kaunas) 43 Suppl 1: 77-80, 2007
47. Terryn W, Poppe B, Wuyts B, Claes K, Maes B, Verbeelen D, Vanholder R, De Boeck K, Lameire N, De Paepe A, De Schoenmakere G: Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant 23: 294-300, 2008
48. Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD, Sirrs S: Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3: 139-145, 2008
49. Porsch DB, Nunes AC, Milani V, Rossato LB, Mattos CB, Tsao M, Netto C, Burin M, Pereira F, Matte U, Giugliani R, Barros EJ: Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail 30: 825-830, 2008
50. Rasaiah VI, Underwood JP, Oreopoulos DG, Medin JA: Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. Nephrol Dial Transplant Plus 1: 129-130, 2008
51. Kleinert J, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, Voigtländer T, Wallner M, Kramar R, Stummvoll HK, Schwarz C, Horn S, Holzer H, Födinger M, Sunder-Plassmann G: Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22: 287-292, 2009